Oddifact

Oddifact operates at the intersection of AI and biotech, utilizing a proprietary platform to identify new therapeutic uses for existing molecules in rare diseases, a vast and underserved market. The company's core activity involves generating high-quality, evidence-backed orphan drug designation (ODD) dossiers for regulatory submission, which it then partners with pharmaceutical companies to develop further. With a stated ambition to have 30 new drugs by 2030, Oddifact has demonstrated early traction, claiming 16 FDA ODD submissions and 11 granted designations. Its business model is primarily platform-based and pre-revenue, relying on partnerships for downstream value capture.

Proprietary AI platform that analyzes existing molecules and scientific evidence to identify high-potential new therapeutic indications for rare diseases. It automates significant portions of the evidence synthesis and regulatory dossier preparation workflow, specifically for Orphan Drug Designation submissions.

Oddifact competes in the broad AI-driven drug discovery sector against companies like Recursion, Exscientia, and BenevolentAI. Its specific focus on rare disease repurposing and automated regulatory dossier creation may differentiate it from more generalized discovery platforms or those focused on novel drug design.